Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ACRS's Cash-to-Debt is ranked higher than
63% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:ACRS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACRS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:ACRS's Interest Coverage is ranked higher than
54% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ACRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ACRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 67.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -46.54
NAS:ACRS's ROE % is ranked lower than
54% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. NAS:ACRS: -46.54 )
Ranked among companies with meaningful ROE % only.
NAS:ACRS' s ROE % Range Over the Past 10 Years
Min: -64.46  Med: -50.58 Max: -36.7
Current: -46.54
-64.46
-36.7
ROA % -44.55
NAS:ACRS's ROA % is ranked lower than
59% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:ACRS: -44.55 )
Ranked among companies with meaningful ROA % only.
NAS:ACRS' s ROA % Range Over the Past 10 Years
Min: -53.93  Med: -36.88 Max: -35.59
Current: -44.55
-53.93
-35.59
ROC (Joel Greenblatt) % -10773.51
NAS:ACRS's ROC (Joel Greenblatt) % is ranked lower than
87% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:ACRS: -10773.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27668.42  Med: -7273.25 Max: -3195.88
Current: -10773.51
-27668.42
-3195.88
GuruFocus has detected 2 Warning Signs with Aclaris Therapeutics Inc $NAS:ACRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ACRS Guru Trades in

ACRS Guru Trades in

ACRS Guru Trades in

Q4 2016

ACRS Guru Trades in Q4 2016

Jim Simons 174,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ACRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:BIESF, NAS:PGNX, NAS:CLLS, NAS:ZIOP, OTCPK:SXMDF, NAS:JNCE, NAS:RPTP, NAS:INSY, NAS:AMAG, NAS:AKAO, NAS:VSAR, NAS:MESO, NAS:IMMU, NAS:AMRN, OTCPK:PHMMF, NAS:ESPR, NAS:CRSP, NAS:EDIT, NYSE:MYOV, NAS:ADRO » details
Traded in other countries:8AT.Germany,
Aclaris Therapeutics Inc is a clinical stage pharmaceutical company. It is engaged in identifying, developing and commercializing differentiated topical drugs to address unmet needs in dermatology.

Aclaris Therapeutics Inc was incorporated in Delaware in July 2012. The Company is a clinical stage pharmaceutical company. It is engaged in identifying, developing and commercializing differentiated topical drugs to address unmet needs in dermatology. Its product includes A-101, a proprietary topical solution for treatment of seborrheic keratosis, or SK, a common non-malignant skin tumor. The Company is also developing A-102, a proprietary topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. The Company is dependent on third-party manufacturers to supply products for research & development activities of its programs, including preclinical and clinical testing. It faces competition from pharmaceutical and specialty pharmaceutical companies, academic institutions and governmental agencies and public & private research institutions. The Company is subject to governmental rules & regulations.

Ratios

vs
industry
vs
history
PB Ratio 4.68
ACRS's PB Ratio is ranked lower than
60% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ACRS: 4.68 )
Ranked among companies with meaningful PB Ratio only.
ACRS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.29
Current: 4.68
0
8.29
Current Ratio 22.27
ACRS's Current Ratio is ranked higher than
94% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ACRS: 22.27 )
Ranked among companies with meaningful Current Ratio only.
ACRS' s Current Ratio Range Over the Past 10 Years
Min: 11.26  Med: 29.37 Max: 55.64
Current: 22.27
11.26
55.64
Quick Ratio 22.27
ACRS's Quick Ratio is ranked higher than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ACRS: 22.27 )
Ranked among companies with meaningful Quick Ratio only.
ACRS' s Quick Ratio Range Over the Past 10 Years
Min: 11.26  Med: 29.37 Max: 55.64
Current: 22.27
11.26
55.64

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.07
ACRS's Price-to-Net-Cash is ranked higher than
53% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. ACRS: 6.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACRS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.42  Med: 5.97 Max: 6.52
Current: 6.07
5.42
6.52
Price-to-Net-Current-Asset-Value 6.01
ACRS's Price-to-Net-Current-Asset-Value is ranked higher than
50% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. ACRS: 6.01 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.36  Med: 5.88 Max: 6.4
Current: 6.01
5.36
6.4
Price-to-Tangible-Book 4.68
ACRS's Price-to-Tangible-Book is ranked lower than
51% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ACRS: 4.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.17  Med: 5.02 Max: 5.87
Current: 4.68
4.17
5.87
Earnings Yield (Greenblatt) % -7.42
ACRS's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ACRS: -7.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.22  Med: 0 Max: 348.19
Current: -7.42
-8.22
348.19

More Statistics

EPS (TTM) $ -2.26
Short Percentage of Float6.36%
52-Week Range $14.68 - 33.25
Shares Outstanding (Mil)26.06
» More Articles for NAS:ACRS

Headlines

Articles On GuruFocus.com
Insiders Roundup: Facebook, Target Mar 03 2017 

More From Other Websites
ACLARIS THERAPEUTICS, INC. Financials Mar 18 2017
Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT Mar 15 2017
Aclaris reports 4Q loss Mar 15 2017
Aclaris reports 4Q loss Mar 15 2017
ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 15 2017
Q4 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open Mar 15 2017
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides... Mar 15 2017
Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic... Feb 27 2017
Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5% Feb 24 2017
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15,... Feb 23 2017
Aclaris Therapeutics to Attend Upcoming Investor Conferences Feb 06 2017
Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO Feb 06 2017
ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Jan 26 2017
Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors Jan 26 2017
Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick Jan 03 2017
Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference Jan 03 2017
Aclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up Dec 09 2016
Why Aclaris (ACRS) Could Be Positioned for a Surge Dec 02 2016
Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5% Nov 30 2016
Edited Transcript of ACRS earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)